Literature DB >> 30535720

Return to activity following revision total hip arthroplasty.

Gareth S Turnbull1, Chloe E H Scott2, Deborah J MacDonald2, Steffen J Breusch2.   

Abstract

BACKGROUND: Demand for revision total hip arthroplasty (RTHA) continues to grow worldwide and is expected to more than double within the next 1-2 decades. The primary aim of this study was to examine return to function following revision THA in a UK population. PATIENTS AND METHODS: We assessed 118 patients (132 RTHAs, mean age 65 years SD 13, range 23-88) at a mean follow-up of 7.9 years (SD 4.4) postoperatively. Preoperative age, gender, BMI, social deprivation, operative indication, comorbidities, activity level (UCLA score) and Oxford Hip Scores (OHS) were recorded. Postoperative UCLA score, OHS, EQ-5D, satisfaction levels and performance in activities of daily living (ADLs) were obtained and univariate and multivariate analysis performed.
RESULTS: Mean UCLA activity score improved following RTHA (p < 0.001): UCLA activity score improved in 37% and was unchanged in 50%; 49% of patients engaged in at least moderate level activities (UCLA score ≥ 6). Patient BMI, gender, age and reason for revision did not influence levels of pain, stiffness or activity at follow-up. Preoperative UCLA activity scores (p < 0.001) independently predicted long-term UCLA scores. Independent predictors (p < 0.05) of poor hip-specific function (OHS) following revision included social deprivation, revision for periprosthetic fracture and lower preoperative OHS. Difficulties with ADLs were associated with increasing deprivation, ≥ 3 comorbidities, and revision for periprosthetic fracture or infection (p < 0.05). Overall, 79% of patients remained satisfied or very satisfied following revision THA. Following RTHA, 10% suffered a dislocation and 13% required reoperation for complications.
CONCLUSION: Revision THA facilitates long-term return to preoperative levels of physical activity in the majority of patients, though activity levels increase in one-third only. Overall over three-quarters are satisfied with their outcome, but revision for periprosthetic fracture or dislocation gives the worse overall outcomes and lower satisfaction levels.

Entities:  

Keywords:  Activity levels; Function; PROMs; Revision hip arthroplasty; Satisfaction

Mesh:

Year:  2018        PMID: 30535720     DOI: 10.1007/s00402-018-3090-y

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN: 0936-8051            Impact factor:   3.067


  5 in total

1.  Uncemented total hip arthroplasty; increased risk of early periprosthetic fracture requiring revision surgery in elderly females.

Authors:  S R Hopman; T S de Windt; J H J van Erp; J E J Bekkers; A de Gast
Journal:  J Orthop       Date:  2021-04-02

2.  Patient-reported outcome after primary and aseptic revision hip arthroplasty: 1-year follow-up of 3,559 primary and 406 revision THAs in an institutional registry.

Authors:  Tina S Wik; Jomar Klaksvik; Otto S Husby; Astrid Rasch; Siri B Winther
Journal:  Acta Orthop       Date:  2022-01-03       Impact factor: 3.717

3.  Satisfactory clinical and radiologic outcomes with a new shorter and modular stem for end-stage hip osteoarthritis: an international prospective multicentre pilot study.

Authors:  Riccardo D'Ambrosi; Aldo Toni; Jaroslaw Czubak; Jorge Guadilla; Lawrence Lieber; Ilaria Mariani; Nicola Ursino
Journal:  SICOT J       Date:  2022-04-04

4.  Clinical and Radiological Outcomes of Revision Total Hip Arthroplasty for Patients with Prior Hartofilakidis Type C Hip Dysplasia.

Authors:  Shengjie Guo; Hao Tang; Zhuyi Ma; Yong Huang; Yixin Zhou
Journal:  Orthop Surg       Date:  2022-09-03       Impact factor: 2.279

5.  The Olympia anatomic polished cemented stem is associated with a high survivorship, excellent hip-specific functional outcome, and high satisfaction levels: follow-up of 239 consecutive patients beyond 15 years.

Authors:  Gareth S Turnbull; Claire Marshall; Jamie A Nicholson; Deborah J MacDonald; Nicholas D Clement; Steffen J Breusch
Journal:  Arch Orthop Trauma Surg       Date:  2021-07-25       Impact factor: 2.928

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.